Podcasts about Novo Nordisk

Crude oil sliding after Iran's strike on a U.S. base in Qatar. The energy impact, and how the broader markets are reacting. Plus The next move for Novo Nordisk, as the pharma company cuts ties with Hims & Hers. What it means for the weight loss drug space, and how their latest trial data is hitting the stock.Fast Money Disclaimer

This episode covers: Cardiology This Week: A concise summary of recent studies Heart disease risk: Framingham Heart Study insights Sudden death in female athletes Mythbusters: Owning a pet reduces the risk of heart disease Host: Susanna Price Guests: Carlos Aguiar, Sabiha Gati, Vasan Ramachandran Want to watch that episode? Go to: https://esc365.escardio.org/event/1809 Want to watch that extended interview on sudden death in athletes? Go to: https://esc365.escardio.org/event/1809?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. The ESC is not liable for any translated content of this video.The English-language always prevails. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Sabiha Gati, Nicolle Kraenkel, Susanna Price and Vasan Ramachandran have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Sabiha Gati Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1809?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1809   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Sabiha Gati, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Episode 2659: Vinnie Tortorich and Chris Shaffer discuss three different topics that are all promoting mixed messages about health, and more. https://vinnietortorich.com/2025/06/promoting-mixed-messages-episode-2659 PLEASE SUPPORT OUR SPONSORS YOU CAN WATCH ALL THE PODCAST EPISODES ON YOUTUBE -  Promoting Mixed Messages Chris discovered an article in VegNews: a vegan Italian cookbook. (5:00) They divert to a bit of Italian-American history, which has had its challenges. (6:00) Back to the VegNews article: They ponder how an Italian meal can be vegan. (12:15) Vinnie's family grew veggies, but all the Italian meals centered around meat. There was a keto trial—a small trial—but testing high cholesterol. (22:00) They discuss how many studies have been misrepresented by not including countries whose cultural diets contain a lot of meat. Blue Zones has been misrepresented as well. The diets vary, and the level of meat is far more than what tends to be represented. The one thing all the Blue Zone cultures have in common is an active outdoor lifestyle. (37:00) If you want to get rid of heart disease, you must get rid of processed foods. (38:00) Lean Mass Hyper Responders have a different starting point to consider. (40:00) High cholesterol (LDL) in and of itself is not necessarily a problem; you need to look at it in conjunction with other factors. (42:00) The ADA launched the American Obesity Association. Novo Nordisk has contributed funds to the ADA. Novo Nordisk is the company that brought us Wegovy. (51:00) GLP-1s are not a Magic Pill; if they were, they wouldn't have deadly side effects. (52:30) The ADA amended its guidelines to say that GLP-1s should be the “first line of defense” of correction for T2 diabetes, rather than lifestyle. (54:00) The ADA is disengenuous because it receives millions of dollars from Big Food corporations each year to *not* tell you to cut out sugar and processed foods. (55:00) The information the ADA gives cannot entirely be trusted because of the sources of funding it receives. Follow Vinnie on X @vinnietortorich. More News If you are interested in the NSNG® VIP group is currently closed for registration, but you can get on the wait list - Don't forget to check out Serena Scott Thomas on Days of Our Lives on the Peacock channel.  “Dirty Keto” is available on Amazon! You can purchase or rent it . Make sure you watch, rate, and review it!   Eat Happy Italian, Anna's next cookbook, is available!  You can go to  You can order it from .  Anna's recipes are in her cookbooks, website, and Substack–they will spice up your day!  Don't forget you can invest in Anna's Eat Happy Kitchen through StartEngine.  Details are at Eat Happy Kitchen.  There's a new NSNG® Foods promo code you can use! The promo code ONLY works on the NSNG® Foods website, NOT on Amazon. https://nsngfoods.com/   PURCHASE  DIRTY KETO (2024) The documentary launched in August 2024! Order it TODAY! This is Vinnie's fourth documentary in just over five years. Visit my new Documentaries HQ to find my films everywhere:  Then, please share my fact-based, health-focused documentary series with your friends and family. Additionally, the more views, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! PURCHASE BEYOND IMPOSSIBLE (2022) Visit my new Documentaries HQ to find my films everywhere:  REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! FAT: A DOCUMENTARY 2 (2021) Visit my new Documentaries HQ to find my films everywhere:  FAT: A DOCUMENTARY (2019) Visit my new Documentaries HQ to find my films everywhere: 

⚠️ Warning: Listening to this episode may cause spontaneous inspiration, side effects include rethinking innovation, falling in love with Denmark, and Googling “intelligent bricks.” Meet Anne C. Fleischer — engineer, innovator, former LEO Pharma exec, and now leading Consumer Engagement & New Business Models for Obesity at Novo Nordisk. She grew up in a village so small that your soccer team was whoever showed up to class that day. She wanted to be a helicopter pilot or a doctor, but got motion sickness and couldn't get into med school...... So she built a new path- literally - constructing heart pump mannequins, NFC-enabled pavement tiles, and eventually digital health products that helped millions.

Hexensabbat voraus

Chinese biotech stocks are breaking out—with deals involving Pfizer, Bristol-Myers Squibb, and BioNTech rewriting the playbook for global pharma partnerships. But will the rally last? Back in Singapore, banks like DBS, OCBC, and UOB are buying back shares at scale. And Q&M Dental’s CEO is doubling down on his stock. Plus: Amazon and Walmart explore launching their own stablecoins—could Visa and Mastercard be in trouble? Hosted by Michelle Martin with Ryan Huang, this episode also touches on Novo Nordisk, Oracle, Pop Mart, Emirates, and Jardine Matheson as we unpack the week in markets. Companies mentioned in this episode: Pfizer, Bristol-Myers Squibb, BioNTech, 3SBio, DBS, OCBC, UOB, Q&M Dental, Amazon, Walmart, Visa, Mastercard, Novo Nordisk, Oracle, Pop Mart, Emirates, Jardine Matheson, SATS, SGX.See omnystudio.com/listener for privacy information.

Karriereklubben var selvfølgelig med på Folkemødet – og vi optog et spritnyt afsnit direkte derfra, som du kan høre nu! Udover brancheskift taler vi også om, hvordan man som ung får erfaring nok til at lande en bestyrelsespost, og hvad man gør, hvis man har en medarbejder, der er overkvalificeret til sit job. Panelet består af: Tanja Villumsen, bestyrelsesmedlem og leder i Novo Nordisk. Peter Kjærgaard, CEO i Formuepleje. Christian Bech Nørhave, chefkonsulent for AI hos Dansk Erhverv. Vært: Caroline Rossmeisl Podcastredaktør: Kasper Søegaard See omnystudio.com/listener for privacy information.

Hvem har været forårets store vindere og tabere? Hvad har været den største skandale, og hvad har været årets mest saftige historie? Det får du svar på i denne udgave af Bundlinjen, der er optaget live på Folkemødet på Bornholm. Her endevender panelet, der består af Søren Linding, Simon Bendtsen og Louise Orbesen, foråret i dansk erhvervsliv og kårer vinderne og taberne blandt topcheferne og virksomhederne. Her kommer panelet forbi den dramatiske fyring af Lars Fruergaard i Novo Nordisk, krænkelsesskandalen i Plesner og Carlsbergs topchef Jacob Aarup-Andersen, der bliver udråbt som den nye superstjerne i dansk erhvervsliv. Deltagere: Louise Orbesen, ledelsesekspert, klummeskribent og podcastvært. Søren Linding, erhvervskommentator på Finans. Simon Bendtsen, chefredaktør på Finans. Vært: Rasmus Bendtsen, nyhedsredaktør på Finans. Podcastredaktør: Kasper Søegaard. Foto: Thomas Lekfeldt.See omnystudio.com/listener for privacy information.

En simpel strategi kunne have tjent ATP milliarder. Israel angriber Irans nukleare faciliteter. Her brager prisen på et sommerhus i vejret. Novo Nordisk sender nyt vægttabs­middel til sidste udviklings­fase. Økonomisk advarsel fra topchef i USA's største bank. Trump er villig til at forlænge toldfrist. USA's plan for Grønland og Panama.   Vært: Trine Duvander (trine.duvander@borsen.dk)

Con la mirada puesta en el Viejo Continente, Luis Benguerel, analista independiente, analiza a BP, Shell, Equinor, Eni, Rheinmettal, Hensoldt, Thales, Leonardo, Novo Nordisk, Adidas, Deutsche Bank, AstraZeneca y Orange.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The American Medical Association is calling for a Senate probe into RFK Jr. after he removed all 17 members of the CDC's vaccine advisory board. They are also urging an immediate reversal of the HHS Secretary's decision. In other news, FDA leaders promise support for gene therapy as it faces challenges, Novo Nordisk invests over $800 million in discovering oral obesity drugs, and a new company, InVitro Cell Research, focuses on interventions to slow aging and prevent age-related diseases. FDA Commissioner Marty Makary and CBER Director Vinay Prasad published an article outlining the FDA's priorities, including accelerating cures and deploying artificial intelligence quickly. Other news includes Lilly's muscle-preserving treatment pact, Vertex laying off staff after axing a diabetes asset, and Genentech reshuffling in South San Francisco. Recursion cuts workforce by 20%.FDA leaders have pledged support to gene therapy makers as the industry faces challenges in commercialization. Despite huge valuations, gene therapies are struggling to reach the market. Poor communication about the value of groundbreaking treatments is hindering their prospects. Right of first negotiation deals do not always lead to mergers and acquisitions, as found by Jefferies in their analysis of licensing deals. Trilink's new comprehensive IVT kit simplifies the production of mRNAs. In other news, Lilly strikes a $650 million deal for a muscle-preserving treatment, Odyssey ends its quest for Nasdaq, BMS expands its radiopharma presence, and SpliceBio secures $135 million in funding for protein splicing medicines. Novo ups its obesity efforts with an $800 million pact, while Cullinan makes a $700 million deal for autoimmune T cell engager in China.Thank you for listening to Pharma and Biotech Daily.

Tusindvis af nybyggede huse ramt af alvorlige fejl. Handel­s­af­tale mellem USA og Kina blev ikke en gamechanger. Dansk bejler til kæmpe krigsordre i mørklagt milliards­trid med canadiere. Demant laver historisk opkøb i Tyskland. Tyskland står foran historisk boost, men der er et stort problem. Novo Nordisk kobler sig på Danmarks supercom­puter. Dansk Industri vil bruge milliarder på afgørende teknologi.   Vært: Trine Duvander (trine.duvander@borsen.dk)

Metabolic dysfunction-associated steatotic liver disease (MASLD), also known as fatty liver disease, is a chronic liver condition that affects nearly 1 in 3 people worldwide. It is closely linked to obesity, type 2 diabetes, and metabolic syndrome. Unchecked, it can progress to a more severe form of disease called Metabolic Dysfunction-Associated Steatohepatitis (MASH). Prognosticating the risk of disease progression in MASLD and MASH has traditionally involved liver biopsy, a process that involves removing a tissue sample with a hollow needle and then examining the sample under a microscope to diagnose and stage disease. However, biopsy has many limitations. Additionally, drug development for MASLD and MASH has proceeded slowly in part due to a reliance on liver biopsy to determine drug efficacy.Recently, increasing evidence is suggesting that non-invasive options, for example, imaging examinations along with blood tests that assess likelihood of disease progression such as the Enhanced Liver Fibrosis (ELF) Test, may effectively reduce the need for the more invasive alternative. Key experts in MASLD and MASH share their perspectives about how clinical evidence supports a shift in the way patients with MASLD and MASH could be evaluated in clinical practice and in research.Host Matt Gee, Director of Collaborations and External Engagement at Siemens Healthineers, is joined by Prof. William Rosenberg, Deputy Director of the Institute for Liver and Digestive Health at University College London as well as Dr. Veronica Miller, Director of the Forum for Collaborative Research at the University of California, Berkeley School of Public Health; Dr. Arun Sanyal, Professor of Medicine, Physiology, and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University; and Dr. Michelle Long, International Medical Vice President of Metabolic Dysfunction-Associated Steatohepatitis at Novo Nordisk and Associate Professor in the Section of Gastroenterology and Hepatology at Boston University.What you'll learn in this episode:Liver biopsy creates several obstacles for patients and has limitationsDrug development faces challenges by the reliance on biopsy as a measure of treatment effectivenessNon-invasive tools may be suitable alternatives to liver biopsy both in clinical practice and in drug developmentConnect with Matt GeeLinkedIn Connect with Veronica MillerLinkedInConnect with William RosenbergLinkedInConnect with Michelle LongLinkedInConnect with Arun SanyalVCU.edu Hosted on Acast. See acast.com/privacy for more information.

Erfahre hier mehr über unseren Partner Scalable Capital - dem Broker mit Flatrate und Zinsen. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Meta kauft 49% von Scale AI. Investoren verkaufen: Rüstung wegen nix, T-Mobile wegen Führungswechsel, BYD wegen Split. Investoren kaufen: Novo Nordisk wegen Führungswechsel, Insmed wegen Studiendaten, Alphabet wegen Cloud. Sonst: J.M. Smucker & Rolls-Royce. OPEC macht mehr. Ölkonzerne machen effizienter (trotz Schweinezyklus). USA dominiert. Europa hat's schwer. Außerdem: Aktivisten bei BP (WKN: 850517) & Phillips 66 (WKN: A1JWQU). Deals bei Chevron (WKN: 852552), ExxonMobil (WKN: 852549) & ConocoPhillips (WKN: 575302). Buffett bei Occidental (WKN: 851921). Diesen Podcast vom 11.06.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

This week the BioSpace team was sent into an after-hours scramble by the news that Health and Human Services Secretary Robert F. Kennedy Jr. had fired the remaining members of the CDC's Advisory Committee on Immunization Practices. The secretary argued in an op-ed that accompanied the announcement that the “clean sweep” was necessary to “reestablish public confidence in vaccine science.” The move came amid heightening rhetoric from Kennedy about the safety of vaccines and sparked concerns that the Secretary will replace the committee with people who sympathize with his anti-vaccine positions. On the drug development front, Metsera once again made waves with new data for an amylin drug candidate showing weight loss of 8.4% at just 36 days. The drug could be a major competitor for Novo Nordisk's Cagrisema, which has failed to meet the sky-high expectations of investors despite being the leading amylin candidate in the space. And cell and gene therapy was back in the spotlight last week when the FDA held a round table discussion with industry leaders aimed at eliminating barriers to approval for these complex medicines. This support from the FDA came as Sarepta became the first company to receive a platform technology designation intended to streamline future gene therapy reviews and create predictability for new drug applications created using the same technologies.Over in Biopharm Executive, BioSpace looks at right of first negotiation deals in light of Sanofi's deal to buy Vigil Neuroscience. How often do these agreements turn into M&A? After some analysis, Jefferies found that a ROFN is not a golden ticket to a buyout.

Weight management expert Dr. Megha Poddar explains the science behind weight loss plateaus and why diets alone often fail in this episode of My Weight Live. She explains how the brain's reward system and our biology work to keep weight high, and highlights how obesity medications can play a role in long-term success.This is a must-listen for anyone interested in understanding the complexities of weight management and learning how to support health in a sustainable way.The medical information in this podcast is provided as an information resource only. It is not in any way intended to be nor should you rely on it as a substitute for professional medical evaluation, diagnosis, advice and treatment.This episode was sponsored by Novo Nordisk. It was created independently by My Weight - What to Know with no influence from Novo Nordisk.

Novo Nordisk og Eli Lilly giver deres bud på fremti­dens vægttabs­me­dicin. Kopimedicin kommer også til Europa. Teslas salg faldt tungt i Danmark i 2024. Dansk iværksætter dropper børsnotering i New York. Forsvarsaktier er braget op og er nu dyrere end tech. Demonstrationer fortsætter i L.A. og soldater sættes ind. Vært: Lasse Ladefoged (lala@borsen.dk)  

Javier Etcheverry, trader profesional, repasa los títulos de ASML, Indra, Rovi, Tesco, Pearson, Enagás o Novo Nordisk, entre otros

Miramos a valores como UBS, Novo Nordisk, Rolls-Royce o Ryanair, con Juan José del valle, de ActivoTrade.

Join obesity experts, Dr Robert Kushner, Rameck Hunt, and Michael Knight, as they discuss the impact of social determinants of health (SDOH) on patients with obesity. • Robert Kushner, MD • Rameck Hunt, MD • Michael Knight, MD This podcast is sponsored by Novo Nordisk and is intended for healthcare professionals.  

Host: Susanna Price Guest: J. Wouter Jukema Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1807 Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis,Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers:  Cardiology this Week: A concise summary of recent studies Coronary sinus reducer: promise in refractory angina Best strategies to reach LDL cholesterol goals in high-risk patients Snapshots Host: Susanna Price Guests: Carlos Aguiar, Rasha Al-Lamee, J. Wouter Jukema, Steffen Petersen Want to watch that episode? Go to: https://esc365.escardio.org/event/1807 Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Rasha Al-Lamee has declared to have potential conflicts of interest to report: speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Trump og Putin talte i telefon om luftangreb. Novo Nordisk står for skud, hvis amerikanske medicinpriser stiger. Nu kommer det sidste slag om Trumps “smukke” lov. Danske virksomheder bliver ramt af Trumps forhøjelse af told på stål og aluminium. USA nedlægger veto mod resolu­tion om våbenhvile i Gaza. Energinet skruer ned for afgifter i fire år. 3,8 mia. kr. er tilbage i kassen efter udbytteskan­dale.   Vært: Trine Duvander (trdu@borsen.dk)

Trump underskriver dekret om at told på stål og aluminium hæves til 50 pct. OECD sænker forventninger til global vækst grundet toldkrig - særligt USA rammes. Inflationen falder til 1,9 pct. i Europa. Danske boligrenter falder. Margrethe Vestager er optimistisk om Europas fremtid. Undersøgelse viser at kvinder tjener mest hos Novo Nordisk. Musk tordner mod Trumps lovpakke. Nvidia er igen verdens mest værdifulde. Vært: Lasse Ladefoged (lala@borsen.dk)  

Jagten efter en ny topchef i Novo Nordisk er i fuld gang, og en lang række kandidater er i spil efter den overraskende fyring af Lars Fruergaard. Men lønningerne i udlandet er visse steder tårnhøje og langt over det, man normalt betaler en ceo selv i danske C25-selskaber. Og så er der den berømte "Novo"-ånd, som handler om meget andet end bare performance og resultater. Hør denne Finans Lyn-analyse og bliv klogere på, hvem der kandiderer til jobbet og hvad lønningerne i toppen af det internationale erhvervsliv ligger på i dag? Gæst: Iben Schmidt, journalist, Finans. Vært: Mads Ring Producer: Mads Ring. Foto: Thomas Lekfeldt.See omnystudio.com/listener for privacy information.

Ørsted står til ny milliardnedskrivning i USA efter forøgelse af told på stål og aluminium. B&O laver store ændringer i Kina. Store skattesmæk på medarbejderaktier rammer fortsat hårdt. Løkke lancerer ny plan for økonomisk diplomati. Ukraines angreb vækker stor opsigt og kan ændre Ruslands position. Novo Nordisk i aktiehopla. Vært: Lasse Ladefoged (lala@borsen.dk)

Join experts in obesity, Dr Robert Kushner, Dr Eden Miller, and Dr Jaime Almandoz as they discuss the complex interactions between various factors that lead to obesity, a chronic, progressive disease with underlying pathophysiology. • Robert Kushner, MD • Eden Miller, MD • Jaime Almandoz, MD This podcast is sponsored by Novo Nordisk and is intended for healthcare professionals.

This week on Fat Science, Dr. Emily Cooper, Andrea Taylor, and Mark Wright answer listener questions from around the world about metabolic health. This mailbag episode explores widely-debated topics like “starvation mode,” weight loss plateaus, the relationship between metabolism and cognitive health, cannabis and metabolism, metabolic effects of liposuction, and the latest on GLP-1 medications.Key Takeaways:Dr. Cooper dispels myths around “starvation mode,” citing research on the long-term metabolic impact of dieting and caloric restriction.Weight loss plateaus are often misunderstood—Dr. Cooper explains the natural adaptations behind them and how to assess true progress.Metabolic health plays a major role in brain function, cognitive decline, depression, and dementia prevention.Cannabis affects metabolic pathways in complex ways, with regular use potentially causing negative metabolic effects.Liposuction can trigger metabolic rebound and rapid fat regain for some patients, especially when leptin levels are low.Updates on GLP-1 meds: Liraglutide is available in generic form, but costs fluctuate. New oral and combination therapies are on the horizon.Personal Stories & Practical Advice:Andrea and Mark reflect on their own journeys with dieting, weight plateaus, and medication.Dr. Cooper shares clinical experiences with metabolic rebound after liposuction and ways to navigate pharmacologic treatments.Correction: Lilly has a lower cash pay for Medicare and Medicaid, but Novo Nordisk is not yet.References related to diet-induced metabolic adaptation, also called biological adaptation and defense of body weight. 1. Keys, A., Brozek, J., Henschel, A., Mickelsen, O., & Taylor, H. L. (1950). The Biology of Human Starvation. University of Minnesota Press.2. Dulloo, A. G. (2021). Physiology of weight regain: Lessons from the classic Minnesota Starvation Experiment on human body composition regulation. Obesity Reviews, 22, e13189.3. Müller, M. J., & Bosy-Westphal, A. (2013). Adaptive thermogenesis with weight loss in humans. Obesity, 21(2), 218-228.4. Rosenbaum, M., & Leibel, R. L. (2010). Adaptive thermogenesis in humans. International Journal of Obesity, 34(S1), S47-S55.5. Fothergill, E., Guo, J., Howard, L., Kerns, J. C., Knuth, N. D., Brychta, R., ... & Hall, K. D. (2016). Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity, 24(8), 1612-1619.6. Johanssen, D. L., Knuth, N. D., Huizenga, R., Rood, J., Ravussin, E., & Hall, K. D. (2012). Metabolic slowing with massive weight loss despite preservation of fat-free mass. Journal of Clinical Endocrinology & Metabolism, 97(7), 2489-2496.7. Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011). Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine, 365(17), 1597-1604.8. MacLean, P. S., Bergouignan, A., Cornier, M. A., & Jackman, M. R. (2011). Biology's response to dieting: the impetus for weight regain. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 301(3), R581-R600Resources:Connect with Dr. Emily Cooper on LinkedIn.Connect with Mark Wright on LinkedIn.Connect with Andrea Taylor on Instagram.Fat Science is a podcast on a mission to explain where our fat really comes from and why it won't go and stay away. We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn't a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice.If you have a question for Dr. Cooper, email us at info@diabesityinstitute.org or dr.c@fatsciencepodcast.com.Fat Science is supported by the non-profit Diabesity Institute which is on a mission to increase access to effective, science-based medical care for those suffering from or at risk for diabesity. https://diabesityresearchfoundation.org/

Tobias Kramer wirft zum Monatsende einen Solo-Blick auf das Echtgeld.tv-Depot – und der hat es in sich! Vier spannende Aktien stehen im Fokus:

Audio roundup of selected biopharma industry content from Scrip over the business week ended 23 May 2025. In this episode: Novo Nordisk's CEO forced out; quantifying biopharma's contribution to the US economy; a history of MASH deals; lift for AstraZeneca's asthma ambitions; and major Japanese firms see US revenue growth. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-XJZXECGBDRDJLCM6FBOJSZNPK4/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Fyringen af Novo Nordisk-direktøren Lars Fruergaard lander som en overraskelse og et mysterie for de fleste. Det hele virker pludseligt og planløst. Og mysteriet bliver kun større af, at beslutningen er truffet af en anden Lars - den tidligere Novo-direktør og nuværende formand for Novo Nordsik Fonden, Lars Rebien. Ingen forstår tilsyneladende, hvad Lars Rebien har gang i - hvorfor ville Lars af med Lars? Det spørgsmål vender vi med DR's erhvervsjournalist, Ole Hall. Vært: Simon Stefanski. Program publiceret i DR Lyd d. 22. maj 2025.

Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.  Further Listening: Trillion Dollar Shot  Why WeightWatchers Wants in on Drugs Like Ozempic   Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

We all know the big economic stories of the year: the trade war, the tariffs. But there's another — even bigger? — story that hasn't been getting the same attention: the Ozempicification of our diets, our bodies and our economy. On this week's TLDR, we take a look at the transformation underway. Plus, economic indicators are telling one story about a potential recession; the headlines are telling another. Which one is right? And, why does it feel like everyone's drinking less alcohol? This episode was hosted by Devin Friedman, business reporter Sarah Rieger and former hedgefunder Matthew Karasz, with an appearance by Armine Yanizyan, Atkinson Fellow on the Future of Workers. Follow us on other platforms, or subscribe to our weekly newsletter: linkin.bio/tldrThe TLDR Podcast is offered by Wealthsimple Media Inc. and is for informational purposes only. The content in the TLDR Podcast is not investment advice, a recommendation to buy or sell assets or securities, and does not represent the views of Wealthsimple Financial Corp or any of its other subsidiaries or affiliates. Wealthsimple Media Inc. does not endorse any third-party views referenced in this content. More information at wealthsimple.com/tldr.

Kara and Scott discuss former President Joe Biden's cancer diagnosis, and the reactions across the political spectrum. Then, Moody's downgrades the U.S. credit rating, and Republicans try to pass Trump's "Big Beautiful Bill." Plus, Walmart and Apple face Trump's bully tactics, Meta delays its new AI model, and Novo Nordisk's CEO is out amid rising competition in the weight loss drug market. Follow us on Instagram and Threads at @pivotpodcastofficial. Follow us on Bluesky at @pivotpod.bsky.social. Follow us on TikTok at @pivotpodcast. Send us your questions by calling us at 855-51-PIVOT, or at nymag.com/pivot. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The turbulence that has come with the Trump administration's policies related to the U.S. biopharmaceutical industry is creating an opening for Europe to bolster its life sciences industry. On the latest BioCentury This Week podcast, BioCentury's editors look at how Europe can capitalize on staffing cuts at FDA and NIH and an uncertain policy environment to lure back talent to bolster regulatory agencies and biotech R&D engines and attract assets and partners from China.The editors also discuss two biotech deals driven by former leaders of BD at Roche, Biomarin's James Sabry and Sophie Kornowski at Boston Pharmaceuticals. Under the leadership of Sabry and CEO Alexander Hardy, Biomarin delivered its first takeout in a decade by acquiring Inozyme as it positions itself to take advantage of a regulatory and policy environment that they believe is favorable to their rare disease strategy. CEO Kornowski, meanwhile, executed on a plan to focus her company on a single liver disease asset that GSK acquired for $1.2 billion up front. Finally, BioCentury's editors discuss the management shake-up at obesity company Novo Nordisk, where Lars Fruergaard Jørgensen, the leader who spearheaded Novo Nordisk's transformation into a dominant player in obesity, is stepping down.Chan Zuckerberg Chicago Biohub is hosting an exclusive, invite-only reception on June 3 — the eve of BioCentury's Grand Rounds conference — gathering top voices in biotech innovation and investment to exchange bold ideas, spark new collaborations and channel the energy of Chicago's thriving innovation ecosystem. If you're interested in attending, please register here. This episode was sponsored by Jeito Capital.View full story: https://www.biocentury.com/article/655964#biotech #biopharma #pharma #lifescience #politics #policy #law00:01 - Sponsor Message: Jeito Capital05:05 - European Biotech's Moment?19:00 - Boston Pharma, Biomarin Deals29:41 - Novo Nordisk CEOTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Rafal Trzaskowski, the liberal mayor expected to win the first round cleanly only squeaked by. We ask what's at stake in the NATO-front-line country now the second round looks so uncertain. In the new world of weight-loss drugs Wegovy, from Novo Nordisk, has reigned supreme—perhaps not for much longer (9:40). And people really do look—but also act—like their dogs (16:51).Get a world of insights by subscribing to Economist Podcasts+. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.

Rafal Trzaskowski, the liberal mayor expected to win the first round cleanly only squeaked by. We ask what's at stake in the NATO-front-line country now the second round looks so uncertain. In the new world of weight-loss drugs Wegovy, from Novo Nordisk, has reigned supreme—perhaps not for much longer (9:40). And people really do look—but also act—like their dogs (16:51).Get a world of insights by subscribing to Economist Podcasts+. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.

Join experts in obesity, Dr Robert Kushner, Dr Aaron Kelly, and Dr Edmond “Trey” Wickham, as they discuss the difficulties of navigating the terrain of adolescent obesity. • Robert Kushner, MD • Aaron Kelly, PhD • Edmond “Trey” Wickham, MD This podcast is sponsored by Novo Nordisk and is intended for healthcare professionals.

當你忙到沒時間吃飯、又不想亂吃，來一杯好喝又營養的 Benefit Body 蛋白飲剛剛好。 植物配方低負擔、取代手搖也沒問題!

In this insightful Market Mondays clip, Rashad Bilal, Ian Dunlap, and Troy Millings break down two of the week's biggest financial headlines that could shake up the markets: President Trump's executive order to lower prescription drug prices and Amazon's strategic acquisition of AMD shares. First, the hosts dive deep into the possible long-term impacts of Trump's new executive order aiming to slash prescription drug costs across the board. They discuss the potential winners—everyday consumers in need of lower medication costs—and the possible losers, notably major pharmaceutical companies that may see profit margins squeezed. The conversation covers how this move could spur much-needed innovation within the healthcare sector, but also draws attention to challenges such as lobbying pressure and lengthy litigation. What does this mean for healthcare stocks like Pfizer, Eli Lilly, Novo Nordisk, Johnson & Johnson, CVS, Amgen, and more? The hosts lay out possible outcomes and the bigger economic picture, including references to Mark Cuban's earlier ideas about drug pricing and fair access.Next up, the crew unpacks the real story behind Amazon's much-discussed “purchase” of $84 million in AMD shares. Is this a direct investment or the result of AMD's acquisition of ZT Group International—where Amazon already had stakes? They clarify the technical details and examine how this plays into Amazon's push for self-reliance in AI infrastructure and chip development, following in the footsteps of giants like Apple making their own chips. The discussion also touches on how this integration of hardware and internal resources could position Amazon for even more dominance in the AI race and tech industry at large.Throughout the clip, Rashad, Ian, and Troy provide honest takes on market strategies, investment insights, and the political chess game playing out in real time. From healthcare innovation to tech self-sufficiency, this conversation is a must-watch for investors, entrepreneurs, and anyone wanting to stay ahead of the curve on Wall Street.Don't forget to like, comment, and subscribe for more in-depth market analysis and actionable insights!#MarketMoves #PrescriptionDrugs #HealthcareStocks #TrumpNews #Amazon #AMD #TechStocks #AI #Investing #StockMarket #Finance #BusinessNews #MarkCuban #Pharma #EliLilly #Pfizer #JohnsonAndJohnson #Pharmaceuticals #Innovation #BusinessAnalysis #AmazonPrime #WallStreet #FinancialNewsSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Join this multidisciplinary discussion with Joseph Arulandu, MD, FACP, Michael Blaha, MD and Melissa Magwire RN, MSN, as they discuss the interconnected nature and the significant co-existence of cardiometabolic diseases. Joseph R. Arulandu, MD, FACP Michael J. Blaha, MD, MPH Melissa Magwire, RN, MSN, CDCES This podcast is sponsored by Novo Nordisk and is intended for healthcare professionals.

Carl Quintanilla, Jim Cramer and David Faber kicked off the hour by discussing the S&P aiming for its 5th straight day of gains, with megacap tech stocks leading the charge. Nvidia and Tesla shares were up double digits since Monday. Faber also broke down the deal of the day, as Charter announced it would acquire Cox Communications to create one of the largest cable companies in the U.S. Also in the mix: Novo Nordisk announced that CEO Lars Jorgensen would be stepping down from his role, citing recent market challenges. Shares of Novo Nordisk were down more than 50% over the last full-year of trading.  Squawk on the Street Disclaimer 

Novo Nordisk, the company that makes the weight loss drugs Ozempic and Wegovy, is abruptly ousting its chief executive, Lars Fruergaard Jørgensen, over concerns the firm is losing ground in the popular weight-loss drug market. Consumer boycotts of countries and companies are on the rise, with the latest being an Indian tourism boycott of Turkey and Azerbaijan. This comes as some Canadians boycott the US, while others refuse to buy from some specific companies over their policies. And Rahul Tandon hears about why some private companies in the USA see an opportunity in this rail sector, as there are concerns over the US federal government looking to pull back from supporting rail.

Ben and Tom discuss the potential Charter and Cox Communications merger, Meta's AI delays, and Novo Nordisk firing its CEO. For information on how to join the Zoom calls live each morning at 8:30 EST, visit:https://www.narwhal.com/blog/daily-market-briefingsPlease see disclosures:https://www.narwhal.com/disclosure

Good bosses are rare. They don't have to be. The skills of management can be learned.The Economist's management columnist, Andrew Palmer, is here to help. The second season of Boss Class features leaders at some of the world's best performing companies, from Levi's to Novo Nordisk to Google. New episodes are out weekly starting May 12th. To listen to the full series, subscribe to Economist Podcasts+. https://subscribenow.economist.com/podcasts-plusIf you're already a subscriber to The Economist, you have full access to all our shows as part of your subscription. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.

Good bosses are rare. They don't have to be. The skills of management can be learned.The Economist's management columnist, Andrew Palmer, is here to help. The second season of Boss Class features leaders at some of the world's best performing companies, from Levi's to Novo Nordisk to Google. New episodes are out weekly starting May 12th. To listen to the full series, subscribe to Economist Podcasts+. https://subscribenow.economist.com/podcasts-plusIf you're already a subscriber to The Economist, you have full access to all our shows as part of your subscription. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.

Good bosses are rare. They don't have to be. The skills of management can be learned.The Economist's management columnist, Andrew Palmer, is here to help. The second season of Boss Class features leaders at some of the world's best performing companies, from Levi's to Novo Nordisk to Google. New episodes are out weekly starting May 12th. To listen to the full series, subscribe to Economist Podcasts+. https://subscribenow.economist.com/podcasts-plusIf you're already a subscriber to The Economist, you have full access to all our shows as part of your subscription. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.

Good bosses are rare. They don't have to be. The skills of management can be learned.The Economist's management columnist, Andrew Palmer, is here to help. The second season of Boss Class features leaders at some of the world's best performing companies, from Levi's to Novo Nordisk to Google. New episodes are out weekly starting May 12th. To listen to the full series, subscribe to Economist Podcasts+. https://subscribenow.economist.com/podcasts-plusIf you're already a subscriber to The Economist, you have full access to all our shows as part of your subscription. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.

Good bosses are rare. They don't have to be. The skills of management can be learned.The Economist's management columnist, Andrew Palmer, is here to help. The second season of Boss Class features leaders at some of the world's best performing companies, from Levi's to Novo Nordisk to Google. New episodes are out weekly starting May 12th. To listen to the full series, subscribe to Economist Podcasts+. https://subscribenow.economist.com/podcasts-plusIf you're already a subscriber to The Economist, you have full access to all our shows as part of your subscription. For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account. Hosted on Acast. See acast.com/privacy for more information.